CMS Cameron McKenna Nabarro Olswang LLP | European Union, United Kingdom | 29 Mar 2017
In response to a reference from the Dutch courts, Advocate General Spzunar (the “AG”) has provided an opinion on whether a P2P file sharing search…
CMS Cameron McKenna Nabarro Olswang LLP | United Kingdom | 23 Mar 2016
The Court of Appeal has reversed the decision of the IPEC in determining an account of profits for patent infringement proceedings. In reaching this…
CMS Cameron McKenna Nabarro Olswang LLP | United Kingdom | 4 Aug 2015
The case of Wobben Properties v Siemens & Ors [2015] EWHC 2114 (Pat), saw the Patents Court considering a technical dispute concerning the alleged…
CMS Cameron McKenna Nabarro Olswang LLP | United Kingdom | 6 Feb 2015
The High Court has refused to grant an interim injunction that Warner-Lambert had requested against Actavis. The order sought to prevent alleged…
CMS Cameron McKenna Nabarro Olswang LLP | United Kingdom | 30 Dec 2013
The CJEU has set aside a decision of the General Court, thereby confirming that proof that the use of a later mark is, or would be, detrimental to the…
CMS Cameron McKenna Nabarro Olswang LLP | United Kingdom | 30 Aug 2013
This case involves the Supreme Court's decision on whether Virgin Atlantic was entitled to claim damages in respect of infringement of its flat bed…
CMS Cameron McKenna Nabarro Olswang LLP | United Kingdom | 21 Sep 2012
The High Court has refused to grant a stay of proceedings for infringement of a Community Trade Mark under Article 104(1) of the CTM Regulation where there were parallel proceedings before OHIM.
CMS Cameron McKenna Nabarro Olswang LLP | European Union, United Kingdom | 19 Jul 2012
The CJEU has ruled on the questions referred to it following the Chartered Institute of Patent Attorney’s appeal against the refusal to allow its registration of “IP TRANSLATOR” in relation to Class 41 of the Nice Classification.
CMS Cameron McKenna Nabarro Olswang LLP | United Kingdom | 30 Sep 2011
Mr Justice Floyd has granted an application for an expedited trial in favour of Teva, in circumstances in which, if Teva succeeds in invalidating Warner-Lambert’s patent, Teva may obtain an advantage over other generic manufacturers of the drug atorvastatin, marketed by Warner-Lambert as Lipitor, one of the world’s most successful drugs with an annual turnover exceeding £350 million.